

FIG. 1A







FIG. 1B




Mock & HaDHR



HaMDR1



Days Post-BMT
Mock & HaDHR



HaMDR1




FIG. 3A

FIG. 3B

MDR1 Transduced
Donor

Non-injected
Recipient

Recipients Injected with
MDR1 Expanded Marrow

15 7 11 18 20





FIG. 3C



Secondary Transplants

FIG. 3D-1

EVENTS




FIG. 3D-2

EVENTS




FIG. 3D-3

EVENTS




FIG. 3D-4

EVENTS





FIG. 3D-5

EVENTS



PgP Fluorescence

FIG. 4




FIG. 5

Negative

Representative Secondary Day 12 CFU-S

Control

CFU-S




FIG. 6A





FIG. 6B





Magnification

10x

50x

FIG. 7B-1

Normal





FIG. 7B-2

Normal

FIG. 7B-3

Abnormal




FIG. 7B-4

Abnormal

FIG. 7B-5

Abnormal





FIG. 7B-6

Abnormal

Day 0

Day 6

Day 12










Figure 8




Figure 9A

B




Figure 9B




Figure 10A





Figure 10B-10C

Figure 11



Ladder
- Control

- 12.1
- 12.2
- 12.3
- 12.4
- 12.5
- 12.6
- 12.7



Ladder
- Control

- 10.1
- 10.2
- 10.3
- 10.4
- 10.5
- 10.6
- 10.7
- 10.8
- 10.9
- 10.10
- 10.11




Figure 12A-12D




Figure 13A-13B




Figure 14A-14D




Figure 15A







Figure 15B



Untreated



+ Verapamil



+ 2-deoxyglucose




Figure 17




Figure 18




Figure 19




Figure 20





Figure 21


Rhesus monkey BM



B



C




BCRP



β -actin

Mouse myoblast



E



Bcrp1



β 2M

Figure 22

A

BCRP

30 25 30 25 30 25 30 25



B

β -actin

M5, (9;11) 90% blasts M1, (46XX) 83% blasts M1, (5;6)(7;13) 94% blasts M5, (46XX) 91% blasts

25 20 25 20 25 20 25 20




Figure 23